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Changes in RANKL during the first two
years after cART initiation in HIV-infected
cART naïve adults
Inger Hee Mathiesen1, Mohammad Salem2, Jan Gerstoft1, Julie Christine Gaardbo1, Niels Obel1, Court Pedersen3,
Henrik Ullum4, Susanne Dam Nielsen1 and Ann-Brit Eg Hansen5*
Abstract
Background: By assessing the changes in concentration of soluble receptor activator of nuclear factor κ B ligand
(RANKL) and osteoprotegrin (OPG) after initiation of combination antiretroviral therapy (cART) in treatment-naïve HIV-
infected patients we aimed to evaluate whether the initial accelerated bone loss could be mediated by increased
soluble RANKL (sRANKL) levels associated with CD4+ T cell recovery.
Methods: We used multiplex immunoassays to determine sRANKL and OPG concentrations in plasma from 48 HIV
patients at baseline and 12, 24, 48 and 96 weeks after cART initiation.
Results: Soluble RANKL changed significantly over time (overall p = 0.02) with 25% decrease (95% CI: -42 to −5) at week
24 compared to baseline and stabilized at a lower level thereafter. We found no correlation between CD4+ T cell count
increment and changes in sRANKL or between percentage change in BMD and changes in sRANKL.
Conclusion: In this study there was no indication that the accelerated bone loss after cART initiation was
mediated by early changes in sRANKL due to CD4+ T cell recovery. Future studies should focus on the initial
weeks after initiation of cART.
Trial registration: Clinical-Trial.gov. id NCT00135460, August 25, 2005. The study was approved by the Danish
Data Protection Agency, Danish Medicines Agency and Regional Ethics Committee.
Keywords: RANKL, OPG, cART, BMD, HIV infection
Background
HIV-infected patients experience a loss in bone mineral
density (BMD) during the first 6–12 months after initi-
ation of combination antiretroviral therapy (cART) [1–5].
The bone loss associated with cART initiation has been
observed for all combinations of drug classes [6] although
Tenofovir disoproxil fumarate (TDF) containing regimens
are associated with more pronounced decreases in BMD
of an additional 1.4%–2.0% [3, 7]. The molecular mecha-
nisms behind the accelerated bone loss are not fully
understood.
A key system in bone turnover is the RANK/RANKL/
OPG system [8]. Receptor activator of Nuclear Factor κ
B(RANK) expressed on osteoclast surfaces binds recep-
tor activator of nuclear factor κ B ligand(RANKL), which
is expressed on osteoblast surfaces but also secreted by
endothelial cells, B lymphocytes and T lymphocytes [9].
Binding of RANKL to RANK initiates a cascade of intra-
cellular pathways which activates gene transcription
necessary for osteoclast maturation and activity [9].
Osteoprotegrin (OPG) is produced by osteoblasts and
works as a decoy receptor of RANKL thus inhibiting
osteoclast activity [9].
A study of HIV-1 transgenic rats reported increased
bone degradation and a shift in the ratio of RANKL to
OPG favouring osteoclastogenesis and hence bone loss
[10], findings which were later validated in HIV positive
subjects [11]. A further study in T-cell depleted knock-
out mice demonstrated that transfusion of T-cells corre-
sponded to increased RANKL concentrations and bone
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loss (BMD evaluated by DXA scan) within the repleted
mice [12]. In other inflammatory conditions such as
chronic colitis, activated CD4 + T cells have been shown
to produce RANKL [13]. These data suggest that the im-
mune reconstitution and/or CD4 + T cell recovery after
cART initiation could be a contributing factor to bone
loss. In a previous study [1], we have shown a significant
bone loss after cART initiation at the spine and femoral
neck after 24 and 48 weeks, respectively. Furthermore,
more pronounced bone loss was found in individuals
with very low CD4 + T cell count at time of cART initi-
ation. Other prospective studies have also found that
low baseline CD4 + T cell count [3], especially CD4 + T
cell count below 50 cells/mm3 [14, 15], was a predictor
of more pronounced bone loss after cART initiation.
In the present study, we aimed to assess the changes in
soluble RANKL (sRANKL) and OPG repeatedly over
96 weeks in treatment-naïve HIV-infected patients initiat-
ing cART. We hypothesized that treatment with cART
would result in increased sRANKL concentration and
altered RANKL/OPG ratio during the first months after
cART initiation due to CD4 + T cell recovery. We also
hypothesized that the early increase in sRANKL concentra-
tions would be negatively correlated with baseline CD4 + T
cell count. Finally, we hypothesized that sRANKL and
RANKL/OPG ratio would correlate negatively with BMD.
Methods
Study population
The SPAR BMD study has been described previously [1].
In this study patients from three Danish centers special-
ized in HIV treatment were randomized to a protease
inhibitor (PI) sparing regimen (zidovudine/lamivudine/
efavirenz) or a nucleoside reverse transcriptase inhibitor
(NRTI) sparing regimen (lopinavir/ritonavir/efavirenz).
Site specific Dual X Ray Absorptiometry (DXA) scans
were performed to evaluate spine and femoral neck BMD
at baseline and week 24, 48, 96 and 144 after initiation of
cART. In the present study, we used stored plasma sam-
ples from patients from the two largest centers to measure
sRANKL and OPG at baseline and week 12, 24, 48 and
96. Three patients received oral corticosteroids during the
study period; two patients within the first study year, and
one patient within the second study year. No patients
received bisphosphonates or other anti-osteoporotic medi-
cation during the study period.
Measurement of soluble RANKL and OPG
At baseline, week 12, 24, 48 and 96 a 10 ml EDTA blood
sample (non-fasting) was drawn. Samples were immediately
centrifuged for 10 min at 3000 g at 0°-4° Celsius, then
plasma was transferred to Nunc™ tubes and frozen immedi-
ately at −80° Celsius until analysis.
Concentration of sRANKL and OPG were determined
by multiplex analysis (Biomedica, Vienna, Austria) ac-
cording to the manufacturer’s instructions. For RANKL,
100 μl of pre-prepared standards/controls and samples
were added to the reaction wells of the microarray, and
100 μl biotinylated anti soluble RANKL antibody was
then added to each well. The plate was incubated over
night at room temperature with continuous shaking.
The following day the antibody-coupled microspheres
were washed 5 times in pre-prepared wash buffer and
incubated with 200 μl streptavidin-alkaline phosphate
for 1 h at room temperature. Then the plate was washed
as above and 100 μl of each amplifier A (inorganic salts
and buffered enzyme solution with tetrazolium violet)
and amplifier B (stabilized NADPH solution) per well
were added and again incubated at room temperature
for 45 min. Finally, 50 μl stop solution was added to
each well and the absorbance was measured immediately
at 490 nm with reference 630 nm.
For OPG, 100 μl assay buffer, 50 μl standards/con-
trols/samples, and 50 μl biotinylated anti OPG antibody
was mixed, added to plate, and incubated over night at
room temperature with continuous shaking. After incu-
bation, antibody-coupled microspheres were washed 5
times in wash buffer and incubated with 200 μl assay
substrate for 20 min at room temperature. The reaction
was then stopped as before and the absorbance was
measured immediately at 450 nm with reference
630 nm. According to the manufacturer the inter-assay
CV was <15% and intra-assay CV was <10% for both
RANKL and OPG. All reads were performed using a
Luminex 100 System (Luminex 100™ platform (Luminex
Corp., Austin, TX, USA) and samples from the same
participant were run on the same plate.
Statistical analyses
Baseline characteristics and measurements of sRANKL,
OPG concentrations, CD4 + T cells and BMD and T
scores were expressed as medians and interquartile range
(IQR) or mean and standard deviation (SD) as appropri-
ate. Differences between groups were compared using
Mann Whitney U test and χ 2 test as appropriate. OPG,
sRANKL and OPG/RANKL ratio were log2 transformed,
and CD4 + T cell count was square rooted to obtain
normal distribution. A linear mixed model (LMM) was
applied to analyze mean changes in sRANKL and OPG
concentrations over time and to analyze whether treat-
ment group was associated with changes in sRANKL or
OPG over time. LMM data was backtransformed and
calculated as percent change from baseline. We used
Student’s T test to compare changes in sRANKL from
baseline (ΔRANKL) at week 12 and 24 in patients with
baseline CD4 + T cell count <200 cells/μl versus patients
with baseline CD4 + T cell count ≥200 cells/μl. Pearson’s
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correlation was used to evaluate correlations between
CD4 + T cell increment (ΔCD4) and ΔRANKL difference
from baseline to week 12. Associations between baseline
RANKL/OPG ratio and BMD and percentage change in
BMD and ΔRANKL at week 12 were also analyzed. Multi-
variate linear regression was used to adjust for age, sex
and BMI at baseline. Statistical analysis was performed
with IBM SPSS Statistics 22. A p value ≤0.05 was consid-
ered significant.
Results
A total of 48 patients with baseline BMD and RANKL/
OPG measurements and at least one follow-up BMD and
RANKL/OPG measurement participated in the BMD
RANKL sub study (23 in the NRTI sparing and 25 in the
PI sparing group). There were no differences in baseline
characteristics (Table 1) and therefore groups were pooled
in the following analyses.
Evolution of BMD over 144 weeks in the randomized
trial has been described in details previously [1]. Major
findings were a marked decrease in BMD at the spine and
femoral neck at week 24 and 48. In the present substudy,
the percentage change from baseline at the lumbar spine
was −2.86 (95% CI; −3.73 to −1.99) at week 24, and −2.26
(95% CI; −3.39 to −1.14) at week 48. The percentage
change from baseline at the femoral neck was −2.59
(95% CI; −4.61 to −1.57) at week 24 and −5.01 (95%
CI; −6.42 to −3.58) at week 48. All changes were sta-
tistically significant (p < 0.001). There were no signifi-
cant differences between the PI-sparing arm and the
NRTI-sparing arm.
Evolution of RANKL and OPG during cART treatment
Over time, sRANKL changed significantly (overall
p = 0.02) with a decline and stabilization from week
24 and onwards.
The mean estimated percent change in sRANKL from
baseline was 2% at week 12 (95% CI: -20 to 31), −25%
(95% CI: -42 to −5) at week 24, −20% (95% CI: -37 to 4)
at week 48 and −27% (95% CI: -45 to −5) at week 96.
OPG levels did not change significantly over time
(overall p = 0.32) although there was a trend towards
an increase from baseline to week 12. The mean esti-
mated change from baseline was 12% (95% CI: 1–24)
at week 12, 5% (95% CI: -6 to 16) at week 24, 8%
(95% CI: -3 to 21) at week 48, and 8% (95% CI: -3
to 22) at week 96. Moreover, RANKL/OPG ratio de-
creased over time, but the changes were not statisti-
cally significant. There was no association between
treatment group and changes in sRANKL over time
(data not shown).
The mean levels of sRANKL, OPG and RANKL/OPG
ratio are depicted in Table 2 and Fig. 1.
Table 1 Baseline characteristics
Entry Overall NRTI sparing PI sparing P level
No 48 23 25 -
Male, (%) 44 (92) 21 (91) 24 (96) 0.90
Age (years) 41.9 (38.12–53.72) 41.30 (38.2–50.9) 41.90 (38.1–54.6) 0.67
Weight (kg) 70.95 (65.17–80.86) 74 (66–88.5) 69.75 (64.4–73.5) 0.06
Height (cm) 178 (173.5–184.75) 178 (172.5–182) 178 (174–186) 0.71
BMI (kg/cm2) 22.03 (20.48–24.94) 23.92 (21.3–25.76) 21.65 (20.46–22.84) 0.06
CD4 + T cell count baseline (cells/μl) 200 (86–280) 240 (110–315) 170 (70–280) 0.20
CD4 + T cell count nadir (cells/μl) 160 (86–250) 200 (110–250) 140 (68–240) 0.21
Spine BMD (g/cm2) 1.09 (0.926–1.20) 1.11 (0.96–1.22) 1.04 (0.96–1.18) 0.38
Spine T-score −0.34 (−1.70–0.71) −0.15 (−1.36–0.83) −0.71 (−1.78–0.40) 0.35
Spine Z-score −0.01 (−1.34–0.85) 0.00 (−0.64–1.2) −0.12 (−1.3–0.74) 0.41
Hip BMD (g/cm2) 0.89 (0.78–0.96) 0.90 (0.81–0.95) 0.86 (0.78–0.96) 0.70
Hip T-score −0.89 (−1.67 - -0.34) −0.86 (−1.5 - -0.37) −0.96 (−1.63 - -0.44) 0.78
Hip Z-score −0.34 (−0.86–0.42) −0.31 (−0.62–0.32) −0.37 (−0.97–0.31) 0.63
HIV RNA (log10 copies/ml) 5.24 (4.69–5.47) 5.01 (4.5–5.7) 5.30 (5.1–5.5) 0.37
RANKL (pg/ml) 7.79 (2.83–12.01) 8.72 (2.79–12.93) 7.38 (2.8–11-93) 0.83
OPG (pg/ml) 34.19 (26.53–45.75) 37.73 (27.95–45.92) 32.08 (24.19–51.72) 0.93
RANKL/OPG ratio 0.21 (0.08–0.36) 0.18 (0.1–0.38) 0.25 (0.07–0.36) 0.82
Continuous data expressed as median and interquartile range (IQR), nominal data expressed as frequency (%)
μl microliter, kg kilograms, cm centimeters, g grams, pg picograms
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CD4+ T cell count and sRANKL concentrations
CD4 + T cell counts are depicted in Table 2. ΔRANKL
at week 12 and week 24 did not differ significantly in the
group of patients with CD4 + T cells below 200 cells/μl
(n = 25) versus patients with CD4 + T cells above 200
cells/μl (n = 23) at baseline in crude analysis and when
adjusted for body mass index(BMI), gender, and age
(data not shown). Neither was there any correlation
between CD4 + T cell increment and ΔRANKL at week
12(r = 0.039, p = 0.81).
RANKL/OPG ratio, sRANKL increment and association with
BMD at baseline and week 24
Baseline RANKL/OPG ratio was not significantly corre-
lated with baseline spine or femoral neck BMD, (r = 0.04
p = 0.78 and r = 0.13 p = 0.41, respectively). This
Table 2 RANKL, OPG and CD4+ T cell count in overall cohort
WEEK sRANKL sOPG RANKL/OPG ratio CD4 + T cells
week 0 7.79 (2.83–12.01) (n = 48) 34.19 (26.53–45.75) (n = 48) 0.21 (0.08–0.36) 200 (86–280) (n = 48)
week 12 8.03 (3.72–11.01) (n = 45) 40.52 (28.55–53.67) (n = 45) 0.18 (0.11–0.30) 300 (202–400) (n = 48)
week 24 5.75 (2.88–9.41) (n = 45) 35.83 (25.54–50.66) (n = 45) 0.17 (0.07–0.29) 340 (240–470) (n = 47)
week 48 5.92 (3.07–11.98) (n = 43) 36.10 (26.19–55.82) (n = 42) 0.16 (0.09–0.35) 360 (250–535) (n = 45)
week 96 6.03 (1.02–11.31) (n = 34) 38.24 (29.82–50.47) (n = 33) 0.15 (0.05–0.30) 450 (280–600) (n = 43)
Values are depicted as median and interquartile range (IQR). sRANKL and OPG in picograms/ml (pg/ml) and CD4+ T cells as cells/μl
* *
Fig. 1 Overall mean RANKL, OPG and RANKL/OPG ratio. Mean levels (95% CI) of (1a) RANKL, (1b) OPG and (1c) RANKL/OPG ratio. Data are
logarithmically transformed. 1 unit change in log2 unit corresponds to a doubling in original unit. *p < 0.05 compared to baseline value
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remained insignificant after adjusting for BMI, gender
and age in multivariate analysis (data not shown). There
was no correlation between week 12 sRANKL increment
and percentage changes in BMD at week 24 at the lum-
bar spine (r = 0.007 p = 0.96) or at the femoral neck
(r = 0.059 p = 0.71), also not in analyses adjusted for
age, BMI and gender.
Discussion
In the present study, we measured sRANKL and OPG at
multiple time points within the first two years after
cART initiation in treatment-naïve HIV-infected pa-
tients. sRANKL values had decreased at week 24 and
stabilized at a lower level thereafter. The decrease
might help to explain the stagnation of cART related
bone loss after 6–9 months of therapy, as a decline in
RANKL levels leads to decreased osteoclast activation.
Similar results with a decline in RANKL levels 6 to
12 months after initiation of cART have been reported
in other studies [16, 17].
In contrast to our hypothesis, we did not detect a signifi-
cant increase in sRANKL at week 12 and our results do not
explain the accelerated BMD loss occurring after cART
initiation. Possibly, changes in soluble RANKL important
for the accelerated bone loss may have taken place already
before week 12, since it is well established that bone
turnover, measured as increasing levels of C-terminal-
telopeptide-cross-links (CTx, a marker of bone degradation
and thereby osteoclast activity), and osteocalcin (OC, a pro-
tein secreted by mineralizing osteoblasts), is accelerated as
early as two weeks after commencing cART [16, 18]. The
observed non-significant decrease in sRANKL to OPG ratio
could reflect that we captured the resetting of bone metab-
olism after a catabolic window within the first weeks after
cART initiation. However, recently published data [18] did
not display any increase in plasma RANKL at week 2,
where a marked increase in bone resorption markers had
already taken place, indicating that sRANKL may not be
the main mediator of bone loss. This is further underscored
by the fact that BMD loss at week 24 did not correlate with
sRANKL increment at week 12 in our study. Combining
these results it seems, that the mechanism of cART in-
duced bone loss was not linked directly to changes in
sRANKL.
Indeed, it has been suggested, that the normal regulation
of bone resorption and bone formation mediated by
RANK/RANKL/OPG, is uncoupled in HIV treatment-
naïve patients in favour of increased osteoclast activity [16].
This will, when bone turnover is increased with cART initi-
ation, lead to the observed accelerated bone loss. Another
explanation of the lack of association between sRANKL
and BMD loss could be, that sRANKL may not reflect what
takes place in the bone microenvironment i.e. direct cross
talk between membrane bound RANKL in osteoblasts and
membrane bound RANK in osteoclasts, which may be of
greater importance of osteoclast activation than soluble
RANKL [19]. Unfortunately we did not have any bone
turnover markers in order to evaluate bone turnover in
context of the observed BMD reductions.
Despite animal models having shown a positive correl-
ation between increasing CD4 + T cell count and
sRANKL and BMD loss [12], we did not find any associ-
ation between changes in sRANKL and baseline CD4 + T
cell count or magnitude of CD4 + T cell recovery in our
present study. In contrast, a recently published study ob-
served significantly increased RANKL levels 12 and
24 weeks after cART initiation coinciding with CD4 + T
cell recovery in a group of patients initiating cART
(n = 19, 18]. These diverting results may be attributable
to several differences in study design including study
population size (n = 48 vs n = 19), difference in ethnic
origin and a TDF-containing regimen in the study by
Ofotokun et al. We also had a lower proportion of
patients with very low CD4 cell counts. In our study,
only five patients (10%) had baseline CD4 + T cell count
below 50 cells/μl, which may have hampered the power
to find an association between CD4+ T cell reconstitu-
tion, changes in sRANKL and changes in BMD.
The major strength of this prospective study is that
we repeatedly measured sRANKL within the two first
years after cART initiation including measurements at
week 12 and 24, the period where the accelerated
bone loss induced by cART initiation peaks. Only one
other group has successfully measured sRANKL levels
at multiple time points within 24 weeks of cART ini-
tiation [18]. In our study, the patients were random-
ized to a cART regimen with or without NRTIs.
Although the regimens are less modern regimens, the
design ensured that we were evaluating the immuno-
logical effect of treatment initiation rather than the
direct drug effect of NRTIs or TDF.
Our study has several limitations. The study popula-
tion is relatively small and there is a risk of type II
error given the large biological variability of sRANKL
[18]. We did not measure any proresorptive cytokines
such as Tumor Necrosis Factor-alpha, interleukin-1 or
interleukin-6 or any bone turnover markers which
would help characterizing the role of sRANKL on
bone turnover just after cART initiation. The degree
of cross validation between different RANKL immune
and ELISA assays are not well established making it
difficult to directly extrapolate results between studies
[20]. Further, blood sampling in this study was not
performed fasting, which may affect within subject
variability; and we only measured sRANKL and not
RANKL expression by B-cells, other immune cells or
osteoblasts. Finally, the majority of participants were
males, and findings may not apply to women.
Mathiesen et al. BMC Infectious Diseases  (2017) 17:262 Page 5 of 7
Conclusion
In summary, we found that sRANKL decreased to levels
below baseline values from week 24 and onwards after
initiation of cART. In our study, in which median base-
line CD4 + T cell count was around 200 cells/μl, there
was no indication that the early cART induced acceler-
ated bone loss was mediated through increased levels of
sRANKL induced by CD4+ T cell recovery. Further
studies focusing on the initial weeks after initiation of
cART are warranted.
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